查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553575

克隆氏症治疗市场规模、份额、趋势分析报告：按类型、给药途径、分销管道、地区、细分市场预测，2024-2030

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

克隆氏症治疗市场的成长和趋势

预计2030年全球克隆氏症治疗市场规模将达162.8亿美元，2024年至2030年复合年增长率预计为2.7%。

由于对该疾病的认识不断提高，加上开发新治疗方法的监管措施不断加强，该市场预计具有很高的成长潜力。

例如，美国胃肠病学协会（AGA）与辉瑞公司合作，支持与发炎性肠道疾病相关的研究计划，并以其名义提供了三项津贴。克罗恩病和结肠炎基金会、欧洲克隆氏症和溃疡性结肠炎协会联合会以及美国自体免疫相关疾病协会是资助这项研究的一些组织。

此外，由于克隆氏症的盛行率不断增加，许多公司正在与各种监管和研究组织合作，推出新的有效的克隆氏症治疗方法。 2016年，辉瑞研发中心（CTI）与约翰霍普金斯大学合作，发现治疗克隆氏症和溃疡性大肠炎的新药。

克隆氏症治疗市场报告亮点

  • 随着透过开发强大的生物疗法和生物相似药来有效管理克隆氏症的药物疗法的进步，非手术疗法将主导市场，到 2023 年将占据 70.3% 的份额。
  • 北美克隆氏症治疗占市场主导地位，2023年占全球收益的60.25%。克隆氏症的高发生率是主要促进因素之一。
  • 该市场的主要参与企业包括强生服务公司、辉瑞公司、艾尔建和艾伯维公司。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章克隆氏症治疗市场变数、趋势、范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 克隆氏症治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章克隆氏症治疗市场：按类型估计和趋势分析

  • 细分仪表板
  • 克隆氏症治疗市场：类型变异分析，百万美元，2023 年和 2030 年
  • 非手术手术
  • 外科手术

第五章克隆氏症治疗市场：依给药途径估计与趋势分析

  • 细分仪表板
  • 克隆氏症治疗市场：给药途径变异分析，百万美元，2023 年和 2030 年
  • 注射
  • 口服

第六章克隆氏症治疗市场：依通路估算与趋势分析

  • 细分仪表板
  • 克隆氏症治疗市场：分销管道变化分析，百万美元，2023 年和 2030 年
  • 医院药房
  • 零售药房
  • 网路药房

第七章克隆氏症治疗市场：区域、估计和趋势分析

  • 2023 年和 2030 年克隆氏症治疗市场占有率（按地区），百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Takeda Pharmaceutical Company Limited
    • AbbVie Inc.
    • Perrigo Company plc
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • Ferring BV
    • Bristol-Myers Squibb Company（Celgene Corporation）
    • F. Hoffmann-La Roche Ltd（Genentech, Inc.）
    • UCB SA
    • Salix Pharmaceuticals
    • Gilead Sciences Inc.
简介目录
Product Code: GVR-2-68038-424-6

Crohn's Disease Therapeutics Market Growth & Trends:

The global crohn's disease therapeutics market size is expected to reach USD 16.28 billion in 2030 and is projected to grow at a CAGR of 2.7% from 2024 to 2030. Increasing awareness of the disease, coupled with rising initiatives by regulatory bodies for development of novel treatment options, is estimated to provide the market with high growth potential.

For instance, the American Gastroenterological Association (AGA), in collaboration with Pfizer, supports research projects related to inflammatory bowel diseases and has offered three grants in their name. The Crohn's & Colitis Foundation, European Federation of Crohn's & Ulcerative Colitis Associations, and American Autoimmune Related Diseases Association are some of the organizations providing funds for research.

Furthermore, increase in prevalence of Crohn's disease has directed many companies to collaborate with various regulatory bodies and research institutes to introduce novel and effective treatment for the condition. In 2016, Pfizer's Centers for Therapeutic Innovation (CTI) collaborated with Johns Hopkins University to discover new medicines to treat Crohn's disease and ulcerative colitis.

Crohn's Disease Therapeutics Market Report Highlights:

  • Non-surgical dominated the market and accounted for a share of 70.3% in 2023 owing to the advancements in medication and the development of powerful biological therapies and biosimilars that effectively manage Crohn's disease
  • North America crohn's disease therapeutics dominated the market in 60.25% of the global revenue in 2023. High incidences of Chron's in patients are one of the major growth drivers
  • Some of the key players in the market are Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; and AbbVie Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Crohn's Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Crohn's Disease Therapeutics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Crohn's Disease Therapeutics Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Crohn's Disease Therapeutics Market: Type Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Non-Surgical
    • 4.3.1. Non-Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. Immune System Suppressors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.4. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Surgical
    • 4.4.1. Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Crohn's Disease Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Crohn's Disease Therapeutics Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Injectable
    • 5.3.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Crohn's Disease Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Crohn's Disease Therapeutics Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Crohn's Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Crohn's Disease Therapeutics Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Takeda Pharmaceutical Company Limited
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. AbbVie Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. Perrigo Company plc
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Pfizer Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. Johnson & Johnson Services Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. Ferring B.V.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Bristol-Myers Squibb Company (Celgene Corporation)
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. F. Hoffmann-La Roche Ltd (Genentech, Inc.)
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. UCB S.A.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Salix Pharmaceuticals
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives
    • 8.4.11. Gilead Sciences Inc.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/Strategic Initiatives